Global Infectious Vaccines Market Research Report 2021

1 Infectious Vaccines Market Overview

• 1.1 Product Overview and Scope of Infectious Vaccines
• 1.2 Infectious Vaccines Segment by Type
  • 1.2.1 Global Infectious Vaccines Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 Preventive vaccine
  • 1.2.3 Therapeutic vaccine
• 1.3 Infectious Vaccines Segment by Application
  • 1.3.1 Infectious Vaccines Sales Comparison by Application: (2021-2027)
  • 1.3.2 Adults
  • 1.3.3 Pediatrics
• 1.4 Global Infectious Vaccines Market Size Estimates and Forecasts
  • 1.4.1 Global Infectious Vaccines Revenue 2016-2027
  • 1.4.2 Global Infectious Vaccines Sales 2016-2027
  • 1.4.3 Infectious Vaccines Market Size by Region: 2016 Versus 2021 Versus 2027

2 Infectious Vaccines Market Competition by Manufacturers

• 2.1 Global Infectious Vaccines Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global Infectious Vaccines Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global Infectious Vaccines Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers Infectious Vaccines Manufacturing Sites, Area Served, Product Type
• 2.5 Infectious Vaccines Market Competitive Situation and Trends
  • 2.5.1 Infectious Vaccines Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Infectious Vaccines Players Market Share by Revenue
  • 2.5.3 Global Infectious Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Infectious Vaccines Retrospective Market Scenario by Region

• 3.1 Global Infectious Vaccines Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.2 Global Infectious Vaccines Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.3 North America Infectious Vaccines Market Facts & Figures by Country
  • 3.3.1 North America Infectious Vaccines Sales by Country
  • 3.3.2 North America Infectious Vaccines Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Infectious Vaccines Market Facts & Figures by Country
  • 3.4.1 Europe Infectious Vaccines Sales by Country
  • 3.4.2 Europe Infectious Vaccines Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Infectious Vaccines Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Infectious Vaccines Sales by Region
  • 3.5.2 Asia Pacific Infectious Vaccines Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Infectious Vaccines Market Facts & Figures by Country
  • 3.6.1 Latin America Infectious Vaccines Sales by Country
  • 3.6.2 Latin America Infectious Vaccines Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa Infectious Vaccines Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Infectious Vaccines Sales by Country
  • 3.7.2 Middle East and Africa Infectious Vaccines Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 U.A.E

4 Global Infectious Vaccines Historic Market Analysis by Type

• 4.1 Global Infectious Vaccines Sales Market Share by Type (2016-2021)
• 4.2 Global Infectious Vaccines Revenue Market Share by Type (2016-2021)
• 4.3 Global Infectious Vaccines Price by Type (2016-2021)

5 Global Infectious Vaccines Historic Market Analysis by Application

• 5.1 Global Infectious Vaccines Sales Market Share by Application (2016-2021)
• 5.2 Global Infectious Vaccines Revenue Market Share by Application (2016-2021)
• 5.3 Global Infectious Vaccines Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 CSL Limited (Australia)
  • 6.1.1 CSL Limited (Australia) Corporation Information
  • 6.1.2 CSL Limited (Australia) Description and Business Overview
  • 6.1.3 CSL Limited (Australia) Infectious Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 CSL Limited (Australia) Product Portfolio
  • 6.1.5 CSL Limited (Australia) Recent Developments/Updates
• 6.2 Bavarian Nordic (Denmark)
  • 6.2.1 Bavarian Nordic (Denmark) Corporation Information
  • 6.2.2 Bavarian Nordic (Denmark) Description and Business Overview
  • 6.2.3 Bavarian Nordic (Denmark) Infectious Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 Bavarian Nordic (Denmark) Product Portfolio
  • 6.2.5 Bavarian Nordic (Denmark) Recent Developments/Updates
• 6.3 GlaxoSmithKline plc. (U.K.)
  • 6.3.1 GlaxoSmithKline plc. (U.K.) Corporation Information
  • 6.3.2 GlaxoSmithKline plc. (U.K.) Description and Business Overview
  • 6.3.3 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 GlaxoSmithKline plc. (U.K.) Product Portfolio
  • 6.3.5 GlaxoSmithKline plc. (U.K.) Recent Developments/Updates
• 6.4 Emergent Bio Solutions Inc. (U.S.)
  • 6.4.1 Emergent Bio Solutions Inc. (U.S.) Corporation Information
  • 6.4.2 Emergent Bio Solutions Inc. (U.S.) Description and Business Overview
  • 6.4.3 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Emergent Bio Solutions Inc. (U.S.) Product Portfolio
  • 6.4.5 Emergent Bio Solutions Inc. (U.S.) Recent Developments/Updates
• 6.5 MedImmune LLC (U.S.)
  • 6.5.1 MedImmune LLC (U.S.) Corporation Information
  • 6.5.2 MedImmune LLC (U.S.) Description and Business Overview
  • 6.5.3 MedImmune LLC (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 MedImmune LLC (U.S.) Product Portfolio
  • 6.5.5 MedImmune LLC (U.S.) Recent Developments/Updates
• 6.6 Johnson and Johnson (U.S.)
  • 6.6.1 Johnson and Johnson (U.S.) Corporation Information
  • 6.6.2 Johnson and Johnson (U.S.) Description and Business Overview
  • 6.6.3 Johnson and Johnson (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 Johnson and Johnson (U.S.) Product Portfolio
  • 6.6.5 Johnson and Johnson (U.S.) Recent Developments/Updates
• 6.7 Novartis AG (Switzerland)
  • 6.6.1 Novartis AG (Switzerland) Corporation Information
  • 6.6.2 Novartis AG (Switzerland) Description and Business Overview
  • 6.6.3 Novartis AG (Switzerland) Infectious Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Novartis AG (Switzerland) Product Portfolio
  • 6.7.5 Novartis AG (Switzerland) Recent Developments/Updates
• 6.8 Merck and Company (U.S.)
  • 6.8.1 Merck and Company (U.S.) Corporation Information
  • 6.8.2 Merck and Company (U.S.) Description and Business Overview
  • 6.8.3 Merck and Company (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Merck and Company (U.S.) Product Portfolio
  • 6.8.5 Merck and Company (U.S.) Recent Developments/Updates
• 6.9 Sanofi Pasteur (France)
  • 6.9.1 Sanofi Pasteur (France) Corporation Information
  • 6.9.2 Sanofi Pasteur (France) Description and Business Overview
  • 6.9.3 Sanofi Pasteur (France) Infectious Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 Sanofi Pasteur (France) Product Portfolio
  • 6.9.5 Sanofi Pasteur (France) Recent Developments/Updates
• 6.10 Pfizer Inc. (U.S.)
  • 6.10.1 Pfizer Inc. (U.S.) Corporation Information
  • 6.10.2 Pfizer Inc. (U.S.) Description and Business Overview
  • 6.10.3 Pfizer Inc. (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2016-2021)
  • 6.10.4 Pfizer Inc. (U.S.) Product Portfolio
  • 6.10.5 Pfizer Inc. (U.S.) Recent Developments/Updates

7 Infectious Vaccines Manufacturing Cost Analysis

• 7.1 Infectious Vaccines Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Infectious Vaccines
• 7.4 Infectious Vaccines Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Infectious Vaccines Distributors List
• 8.3 Infectious Vaccines Customers

9 Infectious Vaccines Market Dynamics

• 9.1 Infectious Vaccines Industry Trends
• 9.2 Infectious Vaccines Growth Drivers
• 9.3 Infectious Vaccines Market Challenges
• 9.4 Infectious Vaccines Market Restraints

10 Global Market Forecast

• 10.1 Infectious Vaccines Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Infectious Vaccines by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of Infectious Vaccines by Type (2022-2027)
• 10.2 Infectious Vaccines Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Infectious Vaccines by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of Infectious Vaccines by Application (2022-2027)
• 10.3 Infectious Vaccines Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Infectious Vaccines by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of Infectious Vaccines by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List